New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
09:23 EDTHPTXHyperion Therapeutics should be bought on any weakness, says JMP Securities
After sales of Hyperion's Ravicti beat expectations in Q2 but the company disclosed a delay in the initiation of its planned Phase 3 hepatic encephalopathy program for Ravicti, JMP Securities thinks any weakness in the stock is a buying opportunity for investors with a long-term focus, and/or an appreciation for the potential value of the company's diabetes program. The firm notes that Phase 3 data for the drug is expected in 1Q15 and keeps an Outperform rating.
News For HPTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
08:23 EDTHPTXHyperion Therapeutics price target lowered to $32 from $38 at Cantor
Cantor cut its price target on Hyperion after the company reported stronger than expected Q3 results but said distributors would work down 10-12 days of inventory in Q4. The company also said that it would spend $7M-$10M on terminating its DiaPep277 program, noted the firm, which keeps a Buy rating on Hyperion.
07:53 EDTHPTXLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use